Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation

Conditions

• HPV-Positive Oropharyngeal Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Head and Neck Cancer

Interventions

• DRUG: Nogapendekin Alfa Inbakicept (NAI)
• BIOLOGICAL: hAd5-HPV Vaccine (IBRX-042)
• DRUG: Nab-Paclitaxel
• DRUG: Cisplatin
• RADIATION: De-Intensified IMRT
• RADIATION: Standard of Care IMRT

Sponsor

ImmunityBio, Inc.